Overview

PSMA PET Imaging of Recurrent Prostate Cancer

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if a new diagnostic research agent named 68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other standard imaging even when the PSA levels are very low.

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid